JianXiang Zou
University of South Florida
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by JianXiang Zou.
Leukemia | 2007
P.K. Epling-Burnette; Jeffrey S. Painter; Dana E. Rollison; Edna Ku; D Vendron; R Widen; David Boulware; JianXiang Zou; Fanqi Bai; Alan F. List
Selected patients with Myelodysplastic Syndromes (MDS) are responsive to immunosuppressive therapy, suggesting that hematopoietic suppressive T cells have a pathogenic role in ineffective hematopoiesis. We assessed T-cell receptor (TCR) clonality through combined flow cytometry and molecular analysis of the complementarity determining region (CDR)-3 of the T-cell receptor-Vβ gene. We identified clonal T cells in 50% of MDS patients (n=52) compared to 5% of age-matched normal controls (n=20). The presence of T-cell clones was not associated with features linked previously to immunosuppression response, including WHO diagnostic category, karyotype, marrow cellularity, IPSS category, sex or age ⩽60. Using flow cytometry to identify expanded Vβ-families, we found that T cells showed greater expansion in the bone marrow compared with peripheral blood, and were characterized as CD8+/CD57+/CD28− effector T cells. Expanded effector T cell were CD62L negative and expressed the natural killer C-lectin-family receptor NKG2D and CD244 (2B4). We conclude that clonal T-cell expansion is common among all MDS prognostic subgroups.
Leukemia | 2009
JianXiang Zou; Dana E. Rollison; David Boulware; Dung-Tsa Chen; Elaine M. Sloand; Pfannes Lv; Jörg J. Goronzy; Fanqi Bai; Jeffrey S. Painter; Sheng Wei; Cosgrove D; Alan F. List; P.K. Epling-Burnette
Response to immunosuppressive therapy (IST) in younger patients with myelodysplastic syndrome (MDS) has been linked to a T-cell-dominant autoimmune process that impairs hematopoiesis. Analysis of the age-adjusted CD4:CD8 ratio in 76 MDS patients compared with 54 healthy controls showed that inadequate CD4+, rather than expansion of CD8+ T cells, was associated with a lower ratio in a group that included both lower and higher risk MDS patients defined by the International Prognostic Scoring System. In younger MDS patients, naive and memory phenotypes defined by CD45RA and CD62L display showed depletion of naive CD4+ and CD8+ T cells, suggesting a possible relationship to IST responsiveness. To determine the correlation between T-cell subset distribution, T-cell turnover and autoimmunity, a cohort of 20 patients were studied before and after IST. The CD4:CD8 ratio correlated inversely with the proliferative T-cell index before treatment in IST-responsive patients, suggesting that proliferation may be linked to accelerated CD4+ T-cell turnover and hematopoietic failure. Our data show seminal findings that both CD4+ and CD8+ T-cell subsets are dysregulated in MDS. Association between these T-cell defects and response to IST suggests that aberrant T-cell homeostasis and chronic activation are critical determinants influencing autoimmune hematopoietic suppression in younger patients.
Blood | 2008
Pearlie K. Epling-Burnette; Lubomir Sokol; Xianhong Chen; Fanqi Bai; Junmin Zhou; Michelle A. Blaskovich; JianXiang Zou; Jeffrey S. Painter; Todd D. Edwards; Lynn C. Moscinski; Jeffrey A. Yoder; Julie Y. Djeu; Said M. Sebti; Thomas P. Loughran; Sheng Wei
Large granular lymphocyte (LGL) leukemia is commonly associated with poor hematopoiesis. The first case of pulmonary artery hypertension (PAH) was observed in a 57-year-old woman with natural killer (NK)-LGL leukemia and transfusion-dependent anemia. Using a genetic approach, we demonstrated that killing of pulmonary endothelial cells by patient NK cells was mediated by dysregulated balance in activating and inhibitory NK-receptor signaling. Elevated pulmonary artery pressure and erythroid differentiation improved after disrupting the NK-receptor signaling pathway with 4 courses of a farnesyltransferase inhibitor, tipifarnib. Coincidental association between PAH and LGL leukemia suggest a causal relationship between the expanded lymphocyte population and these clinical manifestations. This trial is registered at www.ClinicalTrials.gov as NCI 6823.
Leukemia | 2012
Jessica M. McDaniel; JianXiang Zou; William J. Fulp; Dung-Tsa Chen; Alan F. List; P.K. Epling-Burnette
Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation
Cancer Immunology, Immunotherapy | 2012
Fanqi Bai; Alejandro Villagra; JianXiang Zou; Jeffrey S. Painter; Kirby Connolly; Michelle A. Blaskovich; Lubomir Sokol; Said M. Sebti; Julie Y. Djeu; Thomas P. Loughran; Sheng Wei; Eduardo M. Sotomayor; Pearlie K. Epling-Burnette
Large granular lymphocyte (LGL) leukemia is a chronic lymphoproliferative disease in which T-bet [T-box transcription factor 21 gene (tbx21)] overexpression may play a pathogenic role. T-bet orchestrates the differentiation of mature peripheral T-cells into interferon-γ (IFN-γ) and tumor necrosis factor-α producing CD4+ T-helper type I (Th1) and CD8+ T cytotoxic cells that are necessary for antiviral responses. When IL-12 is produced by antigen–presenting cells, T-bet expression is induced, causing direct stimulation of ifng gene transcription while simultaneously acting as a transcriptional repressor of the IL4 gene, which then leads to Th1 dominance and T-helper type 2 differentiation blockade. Additionally, T-bet has been shown to regulate histone acetylation of the ifng promoter and enhancer to loosen condensed DNA, creating greater accessibility for other transcription factor binding, which further amplifies IFNγ production. We found that treatment with a farnesyltransferase inhibitor tipifarnib reduced Th1 cytokines in LGL leukemia patient T-cells and blocked T-bet protein expression and IL-12 responsiveness in T-cells from healthy donors. The mechanism of suppression was based on modulation of histone acetylation of the ifng gene, which culminated in Th1 blockade.
F1000Research | 2010
P.K. Epling-Burnette; Alan F. List; Justine Clark; Ji-Hyun Lee; Kristen A. Jonathan; William J. Fulp; Xiaohong Li; Weipeng Zheng; Rami Komjokji; Jeffrey S. Painter; JianXiang Zou; Sheng Wei; Amber Schmidt; Chiharu Sugimori; Jong Y. Park; Ashley Cole; Dana E. Rollison
1P. K. Epling-Burnette, 2Alan F. List, 3Justine Clark, 4Ji-Hyun Lee, 3Kristen A. Jonathan, 4William Fulp, 4Xiaohong Li, 4Weipeng Zheng, 2Rami Komjokji, 1Jeffrey S. Painter, 1JianXiang Zou, 1Sheng Wei, 1Amber Schmidt, 1Chiharu Sugimori, 3Jong Park, 3Ashley L. Cole and 3Dana E. Rollison. 1Immunology Program and 2Malignant Hematology Division; 3Risk Assessment, Detection and Intervention Program, Division of Cancer Prevention & Control; 4Biostatistics Program; Moffitt Cancer Center, Tampa, FL, USA Poster II-753
Blood | 2007
Pearlie K. Epling-Burnette; Fanqi Bai; Jeffrey S. Painter; Dana E. Rollison; Helmut R. Salih; Matthias Krusch; JianXiang Zou; Edna Ku; Bin Zhong; David Boulware; Lynn C. Moscinski; Sheng Wei; Julie Y. Djeu; Alan F. List
Blood | 2007
Jun Yang; P.K. Epling-Burnette; Jeffrey S. Painter; JianXiang Zou; Fanqi Bai; Sheng Wei; Thomas P. Loughran
Blood | 2007
P.K. Epling-Burnette; Lubomir Sokol; Lynn C. Moscinski; Magda Elkabani; Fanqi Bai; Michelle A. Blaskovich; JianXiang Zou; Jeffrey S. Painter; Said M. Sebti; Thomas P. Loughran
Archive | 2013
JianXiang Zou; Edna Ku; David Boulware; Lynn C. Moscinski; Sheng Wei; Julie Y. Djeu; P.K. Epling-Burnette; Fanqi Bai; Jeffrey S. Painter; Dana Rollison; Helmut Salih; Matthias Krusch